Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR‐Altered Bladder Cancer

Documenti analoghi

• A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer
  di: Shu Cui, et al.
  Pubblicazione: (2025)
• A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
  di: Wei Zhu, et al.
  Pubblicazione: (2026)
• Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations
  di: Wei Zhu, et al.
  Pubblicazione: (2024)
• Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment
  di: Jarett Wallerson, et al.
  Pubblicazione: (2026)
• Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants
  di: Pharavee Jaiprasart, et al.
  Pubblicazione: (2024)